Phase 1 Macular Degeneration Trial, Recruiting NCT07594236 Sponsor: Cellio Therapeutics Inc Condition: Macular Degeneration
Back to Macular Degeneration

Phase 1 Macular Degeneration Trial, Recruiting

NCT07594236
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with a retinal disease that involves breakdown of a layer in the eye called the retinal pigment epithelium (for example, geographic atrophy or Stargardt disease)
  • Your level of vision falls within the specific range required by the trial (confirm with trial site)
  • Your eye condition has been stable for a period of time before joining the trial (confirm with trial site for exact timeframe)
  • You are healthy enough to safely undergo eye surgery and anesthesia
  • You are willing and able to follow all study requirements and attend follow-up appointments

Who may not be able to join:

  • You have or have had abnormal blood vessel growth under the retina (a condition called choroidal neovascularization)
  • You have had a heart attack recently or have serious heart or blood vessel disease that is not well controlled
  • You have glaucoma that is not well controlled
  • You have significant inflammation or swelling inside your eye
  • You have had eye surgery recently within a timeframe set by the trial (confirm with trial site for exact timeframe)
  • You currently have an active infection anywhere in your body
  • You have diabetes that is not well managed (specifically, a blood sugar control measurement called HbA1c above 8.5%)
  • You have taken part in another clinical research study within the past 3 months before screening

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Cellio Therapeutics Inc
Registry
ClinicalTrials.gov
Start date
7 April 2026
Est. completion
31 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of Ocular and Systemic Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov